"BRAF V600E mutations"
"BRAF inhibitors (e.g. vemurafenib) have emerged as a treatment option for refractory or progressive disease in patients with BRAF V600E mutations (approximately 50% of LCH cases) 16,17."
"BRAF inhibitors (e.g. vemurafenib) have emerged as a treatment option for refractory or progressive disease in patients with BRAF V600E mutations (approximately 50% of LCH cases) 16,17."
"Pneumocystis jiroveci pneumonia"
"Pneumocystis jiroveci pneumonia"
"Langerhans cell histiocytosis: general discussion"
Expected headings
"Associations"
"Complications"
"There is preservation of lung volumes or even hyperinflation 1,3,4. Reduced lung volumes are uncommon and only seen in end-stage fibrotic cases 4. Lymph node enlargement visible on chest x-ray is rare 4."